Conclusions and Outlook Therapeutic strategies that exploit FcRn function to enhance degradation of endogeneous IgG or increase serum half-lifes of therapeutic Abs are currently being developed and have the potential to substantially improve the management of MG
Conclusions and Outlook Therapeutic strategies that exploit FcRn function to enhance degradation of endogeneous IgG or increase serum half-lifes of therapeutic Abs are currently being developed and have the potential to substantially improve the management of MG. into the medical center. In this review, we illustrate mechanisms of action and clinical efficacies of emerging Fc-mediated therapeutics such as neonatal Fc receptor (FcRn)-targeting brokers. Furthermore, we evaluate potential customers of therapies targeting classical Fc receptors that have shown encouraging therapeutic efficacy in other antibody-mediated conditions. Increased availability of Fc- and Fc receptor-targeting biologics might foster the development of personalized immunotherapies with the potential to induce sustained disease remission in patients with MG. Keywords: (MG) is the prototypical antibody-mediated autoimmune disease. Pathogenic immunoglobulin G (IgG) antibodies (Abs) bind to acetylcholine receptors (AChR) or to functionally related molecules in the postsynaptic membrane at the neuromuscular junction and induce localized or generalized weakness of skeletal muscle tissue. With an annual incidence of 10 cases per 1 million persons and a prevalence of 250 cases per 1 million, MG and its numerous subgroups (observe also Section 4) are the major diseases that impact the neuromuscular junction [1]. Even though diagnosis is straightforward in most patients with common symptoms and a positive Ab test, the phenotype of the disease and its clinical course including the response to immunotherapy is usually remarkably heterogeneous. Variants of MG are defined on the basis of disease phenotype including severity, age of disease onset, response to first-line therapies and these subgroups influence therapeutic decisions and prognosis (observe also MD2-TLR4-IN-1 Section 4). Unlike other molecules in the immune system, Abs consist of two distinct functional domains: (1) the antigen-binding domain name (Fab) conferring antigen-specificity and binding and (2) the constant fragment crystallizable (Fc) domain name providing instructions to the immune system. Pathogenic functions of AChR-specific Abs mediated by their Fab domain name include blockade of ACh binding to the AChR resulting in inhibition of ACh-dependent signaling at the neuromuscular junction and internalization of the AChR following autoantibody-mediated crosslinking [2]. Fc domain-mediated effector functions of AChR Abs, which predominantly DKFZp686G052 belong to complement-fixing IgG1 and IgG3 subclasses, include activation of match at the postsynaptic membrane resulting in AChR loss and destruction of its characteristic architecture, which is necessary for efficient transmission transduction. The amazing clinical efficacy of pharmacological match inhibition in MG highlights the importance of IgG-Fc mediated match activation in MG pathology [3,4,5]. Cellular infiltrates (mostly macrophages and T cells) are present in MG skeletal muscle mass biopsies [3]. These are rarely topographically related to the neuromuscular junction [3] but are believed to contribute to MG pathology by production of soluble immune factors both locally within the muscle mass environment and systemically, leading to increased serum levels of proinflammatory cytokines [5,6]. Such cellular immune functions are regulated by signaling through Fc receptors (FcR) expressed by many leukocyte subsets [7]. Therapeutic platforms targeting Fc-mediated functions through classical FcRs and the nonclassical major histocompatibility complex (MHC) class I-related neonatal FcR (FcRn), which regulates IgG serum half-life, are currently being developed, tested in clinical trials or have been successfully translated into the medical center for the benefit of patients with MG. Targeted immunotherapy seems to be the most encouraging therapeutic approach in MG because it can effectively overcome the limitations of current nonspecific immunotherapies and has the potential to induce remission. Here, we illustrate the rationale and potential for Fc- and FcR-targeting biologics to treat MG. 2. MG Pathophysiology MG is usually a complex immune-mediated disease characterized by MD2-TLR4-IN-1 circulating Abs that target molecules in the postsynaptic membrane at the neuromuscular junction. Dysregulated activation of T helper (Th)17 and follicular Th cells as well as impaired regulatory T cell (Tregs) function promote MG pathology [8]. Predisposing genetic factors (such as associations with HLADRB1*1501, HLADQ5 and CTLA4 polymorphisms) influence onset and course of disease while the role of triggering environmental cues remains controversial [1]. Approximately 85% of MG patients have detectable Abdominal muscles against the muscle mass nicotinic AChR. This major MG subgroup (AChR MG) encompasses early-onset (EOMG; <50 years of age), late-onset (LOMG; >50 years of age) and thymoma-associated MG (TAMG), all of which show thymic abnormalities [8]. Since the identification of MD2-TLR4-IN-1 the first and most abundant MG antibody target, the AChR, in 1976 [9,10], MG-associated Abdominal muscles directed against other postsynaptic structures, such as muscle-specific kinase (MuSK) [11,12] and lipoprotein-receptor-related protein 4 (LRP4) [13,14] have been described. MuSK- and LRP4-associated MG patients typically depict no thymic abnormalities [1]. The presence of additional Abs against neuromuscular junction-associated molecules such as agrin [15], collagen Q (ColQ) [16] and voltage-gated potassium channel subfamily A.